A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a num­ber of poster pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, re­search re­­sults are made avail­able for review by meeting attendees in the form of posters, each of which summarizes the re­­sults of a single study. Each poster is typ­i­cally about two feet high by three or four feet in length, and all posters during a ses­sion are dis­played throughout a large conference hall.

Most of the myeloma-related …

Saturday was the official first day of the 2014 American Society of Hema­tology (ASH) annual meeting. The day featured a wide range of in­ter­est­ing pre­sen­ta­tions about mul­ti­ple myeloma.

Oral pre­sen­ta­tions about new treat­ments under devel­op­ment were given mid-day and were summarized in a Beacon ASH Daily Update published yes­ter­day morn­ing.

During Saturday evening, a poster session took place where im­por­tant new re­search findings were summarized in posters dis­played throughout two separate large conference halls.

The stud­ies covered a variety of myeloma-related topics, ranging from new treat­ments being devel­oped for myeloma, com­bi­na­tion ther­a­pies …

This year’s American Society of Clinical Oncology (ASCO) annual meeting began yester­day morning in Chicago and will run through Tuesday.

Myeloma-related pre­sen­ta­tions were made during two sessions yes­ter­day.

One session was designed to better educate physicians about per­son­al­ized ther­apy for elderly patients with lymphoid malig­nan­cies. During that session, Dr. Tanya Marya Wildes from the Washington University School of Medicine in St. Louis talked about how to navigate treat­ment options for older multiple myeloma patients.

The key myeloma-related re­search pre­sented yesterday was made public during a poster session in the afternoon about studies …

The American Society of Clinical Oncology will hold its 50^th annual meet­ing May 30 through June 3 in Chicago.

Similar to pre­vi­ous years, more than 25,000 physicians and re­searchers from all over the world are ex­pec­ted to attend the five-day meeting to dis­cuss the current re­search in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all areas of cancer, in­clud­ing many focused specifically on multiple myeloma. The ASCO website cur­rently lists in­for­ma­tion about more than 60 myeloma-related studies (included under either the "multiple myeloma" or "plasma cell …

This article is the second in The Beacon’s ‘preview’ series about mye­lo­ma re­search that will be pre­sented at the American Society of Hema­tol­o­gy (ASH) meet­ing in early December.

Abstracts for the ASH presentations are now available; these abstracts contain pre­lim­i­nary data, and updated data will be presented at the meet­ing.

The Beacon's ASH preview articles, which will be published over the next couple of weeks, will highlight the most interesting myeloma-related studies that will be presented at the meeting.

The first preview, which was published last …

South San Francisco, CA (Press Release) - Threshold Pharma­ceu­ticals, Inc. (NASDAQ:THLD) today an­nounced that clin­i­cal data on its inves­ti­ga­tional hypoxia-targeted drug, TH-302, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The presentations will report early data from two ongoing clin­i­cal trials, one eval­u­ating TH-302 as single-agent mono­therapy in patients with ad­vanced leukemias (Abstract #3920), and another eval­u­ating TH-302 with low-dose dexa­meth­a­sone in patients with re­lapsed / refractory multiple myeloma (Abstract #1948).

Abstract Details

Abstract #1948: Phase 1 Study of TH-302, an Investigational Hypoxia-Targeted …

This year’s American Society of Clinical Oncology (ASCO) annual meeting, which is being held in Chicago, began on Friday and goes through Tuesday.

Sunday started with a poster session in which im­por­tant new re­search findings were summarized on posters dis­played throughout a large conference hall.

The stud­ies pre­sented during the session were on a wide variety of myeloma-related topics, in­clud­ing new treat­ments being devel­oped for myeloma, cur­rently used regi­mens, smol­der­ing mul­ti­ple myeloma, and findings on initial ther­apy.

Some of the posters in­cluded pre­lim­i­nary results from on­go­ing clin­i­cal trials.  Others described the design …